IGF1R and cancer: Our research suggests that Paromomycin may effectively inhibit GBM by targeting HDAC1 to regulate IGF1R SUMOylation, potentially opening new avenues for GBM treatment and inspiring exploration of similar mechanisms in other cancer types (Kunadis et al., 2021).